About the TIMI Study Group
Since its inception in 1984, the principal goal of the TIMI Study Group has been to conduct high quality clinical trials that enhance the care of patients suffering from cardiovascular disease and its risk factors. TIMI has led a wide array of phase 1 to phase 4 trials, as well as registries. These have ranged in size from less than 30 to more than 25,000 subjects. The interventions studied include fibrinolytic, antithrombotic, anti-platelet, anti-ischemic, lipid lowering, anti-inflammatory, and anti-diabetic agents as well as percutaneous coronary intervention. In addition, the TIMI Study Group has used its growing database of more than 300,000 subjects and their clinical findings, electrocardiograms, angiograms, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors. An important corollary goal has been to train the next generation of clinical investigators. TIMI is especially proud of these trainees who have assumed leadership positions in leading institutions around the world.
SUNDAY, NOVEMBER 18TH

Title Growth Differentiation Factor-15 Independently Predicts 2 Year Mortality in Patients with Acute Coronary Syndrome: Observations from the A to Z Trial
Presenter (Poster) Ethan C. Kosova, MD
Session Risk Modifiers in Cardiovascular Disease
Time 9:30 – 11:00 AM
Location South Hall A2, Core 7, Poster 16378

Title Prevalence, Characteristics, Treatment and In-hospital Outcomes of Diabetes Mellitus in Patients with Acute Myocardial Infarction in China from the China Acute Myocardial Infarction Registry
Presenter (Poster) Haiyan Xu, MD, PhD
Session Risk Factors for Cardiovascular Events
Time 9:30 – 11:00 AM
Location South Hall A2, Core 7, Poster 19423

Title Presidential Address: Saving and Improving Lives in the Information Age
Presenter Elliot Antman, MD
Session Opening Session
Time 1:00 – 3:00 PM
Location North Hall B

MONDAY, NOVEMBER 17TH

Title IMPROVE-IT Trial: A comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes after Acute Coronary Syndromes
Presenter Christopher P. Cannon, MD
Session Late Breaking Trials: Anti-Lipid Therapy and Prevention of CAD
Time 10:45 AM – 12:13 PM
Location North Hall B

Title Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Death in Patients after an Acute Coronary Syndrome
Presenter (Poster) Michelle L. O’Donoghue, MD, MPH
Session Insights into the Treatment and Outcomes of Patients with Acute Coronary Syndromes
Time 3:00 – 4:30 PM
Location South Hall A2, Core 7, Poster 17332

TUESDAY, NOVEMBER 18TH

Title Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation: Results from the ENGAGE AF–TIMI 48 Economic Study
Presenter (Poster) Elizabeth A. Magnuson, ScD
Session Anticoagulants for Atrial Fibrillation and Venous Thromboembolic Disease
Time 3:00 – 4:30 PM
Location South Hall A2, Core 7, Poster #17332

Title Safety and Tolerability of very low LDL-C levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)
Presenter (Poster) Michael J. Koren, MD
Session Lipids, Lipoprotein Metabolism and Biomarkers
Time 3:00 – 4:30 PM
Location South Hall A2, Core 2, Poster 16865

Title Multimarker Risk Stratification in Patients with Acute Myocardial Infarction
Presenter (Poster) Michelle L. O’Donoghue, MD, MPH
Session New Developments in Acute Coronary Syndromes
Time 3:00 – 4:30 PM
Location South Hall A2 – Core 7, Poster 17350

Title Pharmacogenetics Versus Other Biomarkers to Guide Clopidogrel Therapy
Presenter (Oral) Jessica L. Mega, MD, MPH
Session Challenges and Opportunities in Personalized Medicine
Time 7:30 – 7:45 AM
Location S104

Title Secondary Observations from SAVOR–TIMI 53 Trial of Saxagliptin
Presenter (Oral) Benjamin M. Scirica, MD, MPH
Session Updates of Cardiovascular Outcomes Trials of Drugs for Diabetes
Time 7:45 – 8:00 AM
Location SS01

Title Cardiometabolic Biomarkers and Long-Term Outcomes in Patients with Type 2 Diabetes Mellitus Treated with Alogliptin vs. Placebo in the EXAMINE Trial
Presenter (Poster) David A. Morrow
Session Diabetes Mellitus and CVD: Prevention and Management IV
Time 9:30 – 11:00 AM
Location South Hall A2, Core 2, Poster 17295

Title IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin vs. Simvastatin Monotherapy on Cardiovascular Outcomes after Acute Coronary Syndromes
Presenter (Poster) Christopher P. Cannon, MD
Session Meet The Trialists
Time 1:00 – 1:45 PM
Location Science & Technology Hall, Booth 870